Pfenex, Inc. is a San Diego–based contract development and manufacturing organization (CDMO) focused on recombinant protein expression. Publicly traded on the NYSE American under the ticker PFNX, the company applies its proprietary Pfenex Expression Technology to the development and production of proteins for biopharmaceutical applications. Its services span process development, analytical method development, cGMP manufacturing and sterile formulation and fill–finish operations.
The Pfenex Expression Technology platform utilizes a modified Pseudomonas fluorescens host system engineered for high-yield, cost-effective production of therapeutic proteins, biosimilar candidates and vaccine antigens. By combining rapid microbial expression with streamlined downstream processing, Pfenex supports preclinical, clinical and commercial campaigns, helping partners reduce scale-up risk and accelerate time to market.
Founded in 2002 and completing its initial public offering in 2014, Pfenex has forged collaborations and supply agreements with pharmaceutical and biotechnology companies across North America, Europe and the Asia-Pacific region. The company’s global footprint and modular manufacturing facilities enable it to address diverse project requirements, from early-stage development through commercial launch.
Under the leadership of President and Chief Executive Officer Jerel Davis, Pfenex continues to invest in facility expansions and technology enhancements. As the biopharmaceutical industry increasingly outsources protein development and manufacturing, Pfenex aims to leverage its platform and flexible operations to meet the evolving needs of its global client base.
AI Generated. May Contain Errors.
